PT - JOURNAL ARTICLE AU - Ygal Rotenstreich AU - Dror Harats AU - Aviv Shaish AU - Eran Pras AU - Michael Belkin TI - Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-<em>cis</em>-β-carotene AID - 10.1136/bjo.2009.167049 DP - 2010 May 01 TA - British Journal of Ophthalmology PG - 616--621 VI - 94 IP - 5 4099 - http://bjo.bmj.com/content/94/5/616.short 4100 - http://bjo.bmj.com/content/94/5/616.full SO - Br J Ophthalmol2010 May 01; 94 AB - Background Fundus albipunctatus is a retinal dystrophy caused by a mutation in the gene encoding 11-cis-retinol dehydrogenase which delays the recovery of rod photoreceptor cells from light stimulation leading to night blindness. A recent study of a mouse model of fundus albipunctatus treated with 9-cis-retinal showed an improvement in visual function and structure.Methods Seven patients with fundus albipunctatus were given a daily food supplement of four capsules containing high-dose 9-cis-β-carotene for 90 days. The subjects were tested before and after treatment by visual field and electroretinogram in both eyes. This non-randomised prospective phase I study was registered at http://www.clinicaltrials.gov (NCT00478530).Results All patients showed significant improvements in peripheral visual field (mean deviation improved from −4.77±2.0 to −3.28±2.28, p=0.009, t test) and a highly significant improvement in rod recovery rates measured electroretinographically (maximal scotopic b-wave amplitude responses, improved from 197±49 μV to 292±48 μV, p&lt;0.001, t test). No complications or side effects were observed.Conclusion Oral treatment with 9-cis-β-carotene led to reversal of a human retinal dystrophy. This potential therapy is readily available and should be evaluated in retinal dystrophies of similar mechanisms such as various types of retinitis pigmentosa.